SMA疾病修正药物对1型患儿急性呼吸衰竭后通气支持的影响
该病例对照研究纳入38例因肺炎并急性呼吸衰竭住院的1型SMA患儿,比较使用与未使用诺西那生或利司扑兰的通气支持结局。治疗组出院半年后无需长期持续依赖机械通气的比例高于未治疗组(69% vs 2/12,P<0.05)。用药时间更长、首次急性呼吸衰竭年龄更大、无基础疾病者更可能避免长期依赖。
要点
- SMA疾病修正药物有助于1型患儿急性呼吸衰竭后避免长期持续依赖机械通气。
- 治疗组出院半年后无需长期依赖机械通气比例高于未治疗组(69% vs 2/12)。
- 用药时间更长、首次呼吸衰竭年龄更大、无基础疾病者更可能避免长期依赖。
核心结论
- SMA疾病修正药物有助于1型患儿在急性呼吸衰竭后避免长期持续依赖机械通气。
- 坚持更长时间用药、首次发生急性呼吸衰竭年龄更大、无基础疾病者更有可能避免长期依赖。
研究设计与样本
- 病例对照研究,纳入2020年1月至2023年7月于首都儿科研究所附属儿童医院因肺炎并急性呼吸衰竭住院的38例1型SMA患儿。
- 根据住院前是否开始并坚持使用诺西那生或利司扑兰分为治疗组(26例)和未治疗组(12例)。
- 治疗组根据出院后半年能否脱离长期持续依赖机械通气分为改善组(18例)与未改善组(8例)。
- 组间比较采用独立样本t检验和χ2检验。
主要发现
- 治疗组出院半年后无需长期持续依赖机械通气者比例高于未治疗组[69%(18/26)比2/12,χ2=9.10,P<0.05]。
- 改善组首次发生急性呼吸衰竭的年龄大于未改善组[1.6(0.4,3.4)比0.5(0.3,0.7)岁,Z=2.07,P<0.05]。
- 改善组用药时间长于未改善组[3.6(2.4,8.7)比1.2(1.2,2.4)月,t=2.74,P<0.05]。
- 改善组合并基础疾病比例小于未改善组(1/18比6/8,χ2=13.58,P<0.05)。
关键数值与推荐
- 治疗组出院半年后无需长期持续依赖机械通气者比例为69%(18/26),未治疗组为2/12。
- 改善组首次发生急性呼吸衰竭年龄为1.6(0.4,3.4)岁,未改善组为0.5(0.3,0.7)岁。
- 改善组用药时间为3.6(2.4,8.7)月,未改善组为1.2(1.2,2.4)月。
- 改善组合并基础疾病比例为1/18,未改善组为6/8。
临床怎么用
- 对1型SMA患儿应尽早开始并坚持使用疾病修正药物,以增加急性呼吸衰竭后避免长期依赖机械通气的可能。
- 评估1型SMA患儿急性呼吸衰竭后通气支持预后时,可关注用药时长、首次呼吸衰竭年龄及是否合并基础疾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To summarize the effects of disease-modifying drugs for spinal muscular atrophy (SMA) on the ventilation support of type 1 children after acute respiratory failure. Methods: A case-control study was conducted, including the data of clinical characteristics, medication and ventilation supports of 38 SMA patients of type 1 with pneumonia and acute respiratory failure hospitalized in Children's Hospital Affiliated to Capital Institute of Pediatrics from January 2020 to July 2023. Children were divided into the treatment group and the untreated group based on whether they started and persisted in using Nusinersen or Risdiplam or not before hospitalization. The differences of ventilation support between the 2 groups were analyzed. The children of the treatment group were divided into the improved group and the unimproved group based on whether they could be avoid of prolonged dependence on continuous mechanical ventilation in the next six months after discharge. The differences in clinical characteristics between the two groups were analyzed. T-test and χ2 test were used for comparison. Results: Among the enrolled children, 19 were male and 19 were female. The age was 1.3 (0.6, 2.0) years at the time of hospitalization due to pneumonia. There were 26 cases in the treatment group and 12 cases in the untreated group. The treatment group had a higher proportion of patients without prolonged dependence on continuous mechanical ventilation in the next six months after discharge (69% (18/26) vs. 2/12, χ2=9.10, P<0.05). Eighteen children were improved among the treated group, while 8 children were not. The improved group had a larger age of first onset of acute respiratory failure (1.6 (0.4, 3.4) vs. 0.5 (0.3, 0.7) years, Z=2.07, P<0.05), a longer duration of medication taken before hospitalization (3.6 (2.4, 8.7) vs. 1.2 (1.2, 2.4) months, t=2.74, P<0.05), and a smaller proportion with underlying diseases (1/18 vs. 6/8, χ2=13.58, P<0.05). Conclusions: SMA disease-modifying drugs are useful for type 1 children to avoid of prolonged dependence on continuous mechanical ventilation after acute respiratory failure. The patients who take medication longer, or have acute respiratory failure for the first-time at an older age, or without underlying diseases are more likely to avoid of. 目的: 总结脊髓性肌萎缩(SMA)疾病修正药物对1型患儿在急性呼吸衰竭后通气支持需求的影响。 方法: 病例对照研究,纳入2020年1月至2023年7月于首都儿科研究所附属儿童医院呼吸内科因肺炎并急性呼吸衰竭住院的38例1型SMA患儿的临床特征、用药及通气支持需求情况。根据住院前是否开始并坚持使用诺西那生或利司扑兰分为治疗组和未治疗组;根据治疗组患儿出院后半年能否脱离长期持续依赖机械通气分为改善组与未改善组。组间比较采用独立样本t检验、χ2检验。 结果: 38例患儿中男女各19例,因肺炎住院年龄1.3(0.6,2.0)岁。治疗组26例、未治疗组12例,治疗组出院半年后无需长期持续依赖机械通气者比例高于未治疗组[69%(18/26)比2/12,χ2=9.10,P<0.05]。改善组18例、未改善组8例,改善组首次发生急性呼吸衰竭的年龄更大[1.6(0.4,3.4)比0.5(0.3,0.7)岁,Z=2.07,P<0.05],用药时间更长[3.6(2.4,8.7)比1.2(1.2,2.4)月,t=2.74,P<0.05],合并基础疾病比例更小(1/18比6/8,χ2=13.58,P<0.05)。 结论: SMA疾病修正药物有助于1型患儿在急性呼吸衰竭后避免长期持续依赖机械通气,坚持更长时间用药、首次发生急性呼吸衰竭年龄更大、无基础疾病者更有可能避免。.
引用
- Guo WH, Sun N, Cao L, et al. [Effect of disease-modifying drugs for spinal muscular atrophy on the ventilation support of type 1 children]. Zhonghua Er Ke Za Zhi. 2024. PMID: 39192445. doi:10.3760/cma.j.cn112140-20240321-00193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。